Pfizer's PADCEV and Keytruda Combo Receives FDA Approval for MIBC

The news announces that Pfizer's important drug combination has received FDA approval, which can be considered a positive catalyst for the stock. Technical indicators also support this optimistic view; the RSI at 66.99 is not approaching overbought territory, and the MACD is trending positively above the signal line. The price is trading above the 20- and 50-day moving averages, maintaining a short-term upward trend. However, given uncertainties about how much the market has already priced in this news and overall market conditions, the bullish expectation can be expressed with moderate confidence.

The news reports that Pfizer has received FDA approval for a drug combination, but this does not directly affect Merck (MRK) stock. Technical indicators present mixed signals: RSI at 52.8 is in neutral territory, while MACD is below zero but approaching the signal line, suggesting a weak bullish bias. The price is above the 20-day moving average but below the 50-day moving average, indicating potential for a short-term recovery. The 1.2% decline over the past 24 hours shows continued selling pressure, though not excessive. Overall, with no direct impact from the news and an unclear technical picture, a sideways movement is expected in the near term.